vimarsana.com

Page 6 - இணை ப்ரிந்ஸிபல் புலனாய்வாளர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Central Coast Voices: My community, Our health

Mi Gente, Nuestra Salud translated from Spanish means, “My community, Our health.” Research shows that expanding opportunities for healthcare benefits everyone. As the pandemic has shown, our health is only as good as that of our most vulnerable community members. Mi Gente, Nuestra Salud, which is a people s movement for health ownership, aims to do this by empowering people from minoritized groups to govern the resources, education, advocacy, and access points that shape good health.  Join Fred Munroe as he speaks with guests involved with Mi Gente, Nuestra Salud, or the Santa Maria People s Movement for Health, Dr. Mario Espinoza-Kulick, MA, PhD, Co-Principal Investigator for Mi Gente, Nuestra Salud and inaugural Ethnic Studies Faculty at Cuesta College, Cristina Macedo, MSW, Coordinator for the Mobile Health Unit at California Polytechnic State University, San Luis Obispo (Cal Poly), and Irma Torres, a student at Cal Poly involved in the project. They will discuss how th

NYU Langone Health to Co-Lead NIH-funded Effort to Understand Long-term Effects of SARS-CoV-2 Infection

INVENTIVA: Inventiva announces three scientific presentations at the EASL International Liver Congress 2021 and during a KOL webcast event

INVENTIVA: Inventiva announces three scientific presentations at the EASL International Liver Congress 2021 and during a KOL webcast event the beneficial effects of lanifibranor on cardiovascular risk biomarkers in patients with NASH the positive effects of lanifibranor on several biomarkers of disease activity and associated risks in patients with NASH and F2/F3 fibrosis One poster presentation showing the beneficial effects of the combination treatment of lanifibranor and ACC1/2 inhibitor firsocostat from Gilead Inventiva will host a dedicated Key Opinion Leader (KOL) webcast event for investors and analysts on June 29, 2021 Daix (France), June 9, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that three abstracts

Investegate |INVENTIVA Announcements | INVENTIVA: Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2021 and during a KOL webcast event

Important Notice This press release contains forward-looking statements, forecasts and estimates with respect to Inventiva’s clinical trials, clinical trial data releases, clinical development plans and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Ac

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.